Tag: LimFlow

PROMISE I: LimFlow system enables vast majority of patients to avoid...

LimFlow SA has announced the presentation of one-year data from the full patient cohort in its PROMISE I study of the LimFlow percutaneous deep...

Positive two-year data from ALPS registry of LimFlow system published

LimFlow SA today announced publication of positive two-year data from the ALPS registry of the LimFlow percutaneous deep vein arterialisation (pDVA) system. Results were...
LimFlow stent provides CLTI Patients relief

First CLTI patient enrolled in PROMISE II pivotal study of LimFlow...

LimFlow, a specialist in minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), has announced...

PROMISE I trial affirms potential of LimFlow system for treatment of...

Initial findings of an early feasibility trial have demonstrated that the LimFlow System does represent a safe and reproducible method of treating patients with...
Daniel Clair

VIVA 2019: PROMISE I trial shows deep vein arterialisation offers hope...

Daniel Clair (Columbia, SC, USA), presented positive six-month data from the full patient cohort of the PROMISE I early feasibility study of the LimFlow...
limflow stent

VIVA 2019: LimFlow announces positive six-month data From PROMISE I US...

LimFlow SA today announced the presentation of positive six-month data from the full patient cohort in its PROMISE I early feasibility study of the...
limflow stent

LimFlow raises €27 million in Series C financing

LimFlow, a developer of peripheral endovascular technology focused on the treatment of critical limb ischemia (CLI), has announced it has secured €27 million (US$33.5...

LimFlow completes enrolment in US feasibility study

LimFlow has announced completion of enrolment of the original 10-patient cohort in the US feasibility study of the LimFlow percutaneous deep vein arterialisation system....
limflow stent

Positive results from pilot study of LimFlow Percutaneous Deep Vein Arterialization...

LimFlow announced on 1 August 2017 publication of positive results from the pilot study of the LimFlow Percutaneous Deep Vein Arterialization System (pDVA) in...

First patient treated in LimFlow US feasibility study as international post-market...

LimFlow SA has announced enrolment of the first patient in the US feasibility study of the LimFlow percutaneous deep vein arterialisation (pDVA) system, a novel,...

LimFlow expands senior management team and opens Silicon Valley office

LimFlow, developer of minimally-invasive technology for the treatment of end-stage critical limb ischaemia (CLI), has announced the expansion of the company’s senior management team....

US FDA grants IDE approval to LimFlow for Percutaneous Deep Vein...

The US Food and Drug Administration (FDA) has approved LimFlow’s Investigational Device Exemption for a feasibility study of the company’s Percutaneous Deep Vein Arterialisation...

LimFlow receives CE mark for percutaneous critical limb perfusion system

LimFlow has received CE mark for its fully percutaneous LimFlow system designed for venous arterialisation of the lower limbs in end-stage patients at risk...